Webinar Date/Time: Wed, Oct 16, 2024 2:00 PM EDT
Drive more value from your real-world evidence (RWE) studies with a novel method that delivers richer insights into patient outcomes and paves the way for better patient care.
Register Free: https://www.pharmexec.com/pe_w/innovative-data-solutions
Event Overview:
Extracting meaningful insights from real-world data (RWD) is essential for organizations focused on improving patient outcomes and reducing health care costs. In this exclusive NTT DATA webinar, you’ll learn how the Charlson Comorbidity Index can significantly deepen the insights you gain from your real-world evidence (RWE) studies. We’ll dive into real-world examples that show how this approach can enhance your understanding of complex patient conditions. We will describe the evolution of health profiles in congestive heart failure (CHF) patients as a key case study that is based on NTT DATA’s Health Data Bank. Don’t miss this chance to see for yourself the real-world approach that can transform your RWE strategies.
Key Learning Objectives
Who Should Attend
Speakers
Mark Feeney, MA
Advisor, Healthcare Analytics
NTT DATA
Mark Feeney, MA, is an accomplished health care analytics professional, with 25-plus years of diverse experience within the life science industry at leading service providers to the pharma industry. He holds a master’s degree from Binghamton University. His areas of expertise include applying real-world evidence solutions to provide key insights to pharma executives; health economics and outcomes research (HEOR) analysis; and real-world data, including patient-level claims, lab and electronic health records (EHR), HEOR, sales force effectiveness and geomarketing analysis.
Madhur Garg
Consultant, RWE, HEOR, Market Access
NTT DATA
Madhur Garg has 15-plus years of health care experience and is a market access strategist with hands-on RWE and HEOR skills. He has experience across pharma and CRO settings leading cross-functional teams at regional and global levels, including at Johnson & Johnson, Lundbeck and LEO Pharma). Garg has experience with all major payers and health technology assessment (HTA) bodies across Europe, North America and the Asia-Pacific region.
Pierre Etienne, MD
Independent Medical Advisor
Pierre Etienne, MD, is a pharma industry veteran with 30-plus years’ experience in large pharma and in leading small biotech firms; spearheading large initiatives and securing funding; and in psychiatry practice and research for 10-plus years. He is chief medical officer and cofounder of Actu-Real Inc, is codirector of the Alzheimer’s disease prevention program (Stop-AD) and is director of the Clinical Research Division at the Douglas Research Centre at McGill University. Prior to joining McGill University in 2009, he was CEO of PhageTech Inc and then CDO at Targanta Therapeutics Inc (whose assets were acquired by Melinta Therapeutics). During 17 years at Pfizer US, he successively led the experimental medicine group, the early clinical research group, clinical operations (including biometrics), and, after the merger with Warner-Lambert, P3 study management and monitoring worldwide.
Register Free: https://www.pharmexec.com/pe_w/innovative-data-solutions
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.